CLEVELAND, March 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc.
Management of Cleveland BioLabs will give a presentation on the Company followed by a question and answer session on March 27, at 4:05 p.m. EDT. The presentation will be broadcast live over the Internet and archived for 60 days, thereafter. Interested parties may register for access to the presentation by visiting the company's website at: www.cbiolabs.com or alternatively at http://www.visualwebcaster.com/ValueRichMiami07/reg.html .
Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer.
The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from regulated cell death. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation- induced damage. Other applications for this technology include protection from cancer treatment side effects.
The Company recently announced that it plans to submit CBLB502 to the Department of Defense in response to a recently published Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase, thereafter.
The ValueRich Small-Cap Financial Expo in Miami will feature the CEOs and executive teams of 50 small-cap public companies. The Expo offers two days of expo-style exhibition, executive leadership business development, networking events, and traditional financial presentations before thousands of investment bankers, fund managers, institutional and accredited investors, and research analysts. For more information about the Expo, please visitwww.vrexpo.net.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006.
Contact:
The Global Consulting Group
Rachel Levine
T: (646) 284-9439
E: rlevine@hfgcg.com